K. Oliner

发表

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Johannes G. Reiter, M. Nowak, K. Kinzler, 2012, Nature.

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

M. Choti, J. Cameron, L. Wood, 2014, Science Translational Medicine.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

J. Hecht, G. Fasola, J. Canon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.

Bing‐Bing Yang, T. Tamura, T. Yoshino, 2011, Japanese journal of clinical oncology.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

A. Cmelak, M. Ozsahin, J. Giralt, 2015, The Lancet. Oncology.

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

H. Minn, A. Cmelak, A. Fortin, 2015, The Lancet. Oncology.

Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC)

Y. Humblet, S. Patterson, M. Peeters, 2010 .

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

E. Jonasch, F. Kabbinavar, W. Stadler, 2011, BJU international.

Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).

G. Fasola, J. Canon, F. Rivera, 2013 .

Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.

S. Faivre, E. Winquist, S. Rottey, 2012 .

Phase 2, Randomized Trial (CONCERT-2) of Panitumumab (PMAB) Plus Radiotherapy (PRT) Compared with Chemoradiotherapy (CRT) in Patients (PTS) with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)

J. Giralt, S. Nuyts, K. Składowski, 2012 .

Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer

Yilong Zhang, S. Doshi, K. Oliner, 2015, Clinical Cancer Research.

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.

J. P. Perez Ruixo, Yilong Zhang, S. Doshi, 2014, Journal of pharmaceutical sciences.

6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2011 .

A phase II study evaluating the efﬁcacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

P. Wen, T. Cloughesy, D. Schiff, 2011 .

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D. Cunningham, B. Karaszewska, M. Tejani, 2015 .

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Y. Humblet, S. Patterson, M. Peeters, 2013 .

549PIMPACT OF TUMOUR RAS/BRAF STATUS ON EFFICACY OF FIRST-LINE PANITUMUMAB + FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC).

R. Greil, C. Köhne, R. Hofheinz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

A. Bardelli, J. Tabernero, M. Boedigheimer, 2015 .

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

R. Donehower, Yi-zhou Jiang, K. Oliner, 2014, The Lancet. Oncology.

Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study.

H. Sørensen, R. Erichsen, M. Kelsh, 2016, Annals of epidemiology.

Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.

R. Donehower, Yi-zhou Jiang, S. Doshi, 2012 .

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

M. Boedigheimer, J. Buyon, M. Damore, 2015, Arthritis & rheumatology.

Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

L. Shen, Y. Hei, Zhi Peng, 2015, Molecular Cancer Therapeutics.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

S. Faivre, L. Licitra, E. Winquist, 2013, The Lancet. Oncology.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel

Ashish Choudhary, Alex T Adai, A. Adai, 2014, BMC Medical Genomics.

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

E. Van Cutsem, Y. Humblet, S. Patterson, 2013, Clinical Cancer Research.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

J. Hecht, A. Grothey, S. Kopetz, 2015, Cancer treatment reviews.

A comparability study of 5 commercial KRAS tests

Daniel J. Freeman, I. Sarosi, S. Patterson, 2010, Diagnostic pathology.

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

R. Donehower, S. Doshi, K. Oliner, 2015, British Journal of Cancer.

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

R. Fisher, B. O'Sullivan, A. Giaccia, 2012, Clinical Cancer Research.

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

R. Fisher, B. O'Sullivan, A. Giaccia, 2012, Clinical Cancer Research.

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

A. Coxon, D. Branstetter, T. Burgess, 2010, Clinical Cancer Research.

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

P. Wen, T. Cloughesy, D. Schiff, 2011, Neuro-oncology.

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

Dorothy J. Park, C. Sweeney, K. Oliner, 2010, Clinical Cancer Research.

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

S. Dakhil, P. Debruyne, L. Wirth, 2016, Oral oncology.

Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (−) Recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 SPECTRUM Trial

E. Winquist, Zhiying Pan, J. Vermorken, 2011 .

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2012 .

A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

H. Minn, A. Cmelak, A. Fortin, 2012 .

Comparability testing of KRAS mutations and association with efficacy from a phase 3 randomized trial of panitumumab (pmab)

Daniel J. Freeman, E. Van Cutsem, I. Sarosi, 2009 .

O-0011 Evaluation of Met-Pathway Biomarkers in a Phase 2 Study of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine in Gastric/Esophagogastric Junction Cancer

R. Donehower, Yi-zhou Jiang, K. Oliner, 2012 .

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

R. Fisher, B. O'Sullivan, A. Giaccia, 2012, Clinical Cancer Research.

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

E. Jonasch, F. Kabbinavar, W. Stadler, 2011, BJU international.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

S. Dakhil, P. Debruyne, L. Wirth, 2013 .

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

P. Wen, T. Cloughesy, D. Schiff, 2011, Neuro-oncology.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.